

**Antibody to CD22**  
**MOUSE MONOCLONAL**

**Catalog Number:** AB-36  
**Quantity:** 100 micrograms  
**Format:** PBS (0.14 M Sodium Chloride; 0.003 M Potassium Chloride; 0.002 M Potassium Phosphate; 0.01 M Sodium Phosphate; pH 7.4), no preservative.  
**Host:** Mouse  
**Isotype:** IgG<sub>1</sub> k  
**Clone:** UV22-2  
**Immunogen:** Daudi cells from a Burkitt's lymphoma

**Background:**

CD22 is characterized as a doublet of 130/140 kDa and is expressed on the surface of normal human B-cells and some neoplastic B-cell lines and tumors. CD22 has also been further divided into four different epitope groups, A, B, C, and D, which represent groups of determinants situated on different portions of the CD22 molecule.

**Specificity and Preparation:**

This IgG<sub>1</sub> k antibody recognizes the group-A epitope of the human B-cell antigen, CD22. Clone UV22-2 reacts exclusively with cells of normal human B-cell lineage. Daudi cells from a Burkitt's lymphoma were used as immunogen. This antibody is routinely tested by flow cytometry.


**Usage and Storage:**

Applications include flow cytometry (0.5  $\mu$ g per  $1 \times 10^6$  cells, ATS in-house), indirect immunofluorescence (0.001-10  $\mu$ g/ml /  $1.5 \times 10^6$  cells)<sup>1</sup>, radiolabeling and immunoprecipitation<sup>1</sup>, radioimmunoassay<sup>1</sup>, immunoperoxidase staining (human tissues)<sup>1</sup>, targeting (targeting agent in Anti-CD22-SAP, Cat. #IT-37). The material should be stored at 4°C. Avoid repeated freezing and thawing. Gently spin down material before use; 5-10 seconds in a microfuge should be adequate.

**References:**

1. Li JL, Shen GL, Ghetie MA, May RD, Till M, Ghetie V, Uhr JW, Janossy G, Thorpe PE, Amlot P, et al. (1989) The epitope specificity and tissue reactivity of four murine monoclonal anti-CD22 antibodies. *Cell Immunol* 118(1):85-99.
2. Shen GL, Li JL, Ghetie MA, Ghetie V, May RD, Till M, Brown AN, Relf M, Knowles P, Uhr JW, et al. (1988) Evaluation of four CD22 antibodies as ricin A chain-containing immunotoxins for the in vivo therapy of human B-cell leukemias and lymphomas. *Int J Cancer* 42(5):792-797.

**To view protocol(s) for this and other products please visit: [www.ATSBio.com/support/protocols](http://www.ATSBio.com/support/protocols)**



Daudi cells, a Burkitt lymphoma cell line, were treated with 0.5  $\mu$ g per  $10^6$  cells of Anti-CD22 mouse monoclonal and subsequently with anti-murine IgG-FITC (Cat. #FL-07). A 99% shift is seen as compared to the secondary alone.